Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
311526.pdf - Published Version Available under License Creative Commons Attribution. 981kB |
| Item Type: | Articles |
|---|---|
| Additional Information: | SR receives support through an unrestricted grant from Roche Diagnostics. NNL and MCP are supported by a British Heart Foundation Centre of Research Excellence Award (BHF RE/18/6/34217). |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Mark, Professor Patrick and Lees, Jennifer and Venugopal, Dr Balaji and Rankin, Dr Stephen and Petrie, Professor Mark and Jones, Professor Robert and Lang, Professor Ninian and Elyan, Dr Benjamin |
| Authors: | Lang, N., Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B., Lees, J., Petrie, M., and Lang, N. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | JACC: CardioOncology |
| Publisher: | Elsevier |
| ISSN: | 2666-0873 |
| ISSN (Online): | 2666-0873 |
| Published Online: | 27 February 2024 |
| Copyright Holders: | Copyright: © 2024 The Authors |
| First Published: | First published in JACC: CardioOncology 6(2): 267-279 |
| Publisher Policy: | Reproduced under a Creative Commons Licence |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information